Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.

abstract：PURPOSE:Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Masuda H,Masuda N,Kodama Y,Ogawa M,Karita M,Yamamura J,Tsukuda K,Doihara H,Miyoshi S,Mano M,Nakamori S,Tsujinaka T

更新日期：2011-04-01 00:00:00

abstract：:The orally bioavailable matrix metalloproteinase inhibitor MMI270 reduces tumour growth metastasis in preclinical models. We assessed the feasibility and pharmacokinetic interactions of combining MMI270 with 5-fluorouracil (5-FU) and folinic acid (FA). Entered into the study were 33 patients with advanced colorectal c...

journal_title：Cancer chemotherapy and pharmacology

authors： Eatock M,Cassidy J,Johnson J,Morrison R,Devlin M,Blackey R,Owen S,Choi L,Twelves C

更新日期：2005-01-01 00:00:00

abstract：:A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen JB,Bach F,Dombernowsky P,Hansen HH

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced m...

journal_title：Cancer chemotherapy and pharmacology

authors： Spieth K,Kaufmann R,Gille J

更新日期：2003-11-01 00:00:00

abstract：:Intravenous (i.v.) administration of sodium thiosulfate reduces the toxicity of cis-diamminedichloroplatinum (II) (CDDP). This effect, which allows the use of increased CDDP doses, has been exploited clinically in the intraperitoneal (i.p.) treatment of intraabdominal tumors. Recently, attempts have been made to treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Aamdal S,Fodstad O,Pihl A

更新日期：1988-01-01 00:00:00

abstract：:The acute and chronic cardiotoxicity and cytotoxicity of the novel doxorubicin (DXR) derivative 4'-amino-3'-hydroxy-DXR were compared with those of 4'-deoxy-DXR and DXR. In the acute cardiotoxicity study, the ECG and hemodynamic changes recorded in anesthetized rats that had been treated i.v. with 10 mg/kg 4'-amino-3'...

journal_title：Cancer chemotherapy and pharmacology

authors： Danesi R,Bernardini N,Agen C,Costa M,Zaccaro L,Pieracci D,Malvaldi G,Del Tacca M

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:To characterise the pharmacokinetics and metabolism in mice of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862), the lead compound of a new class of bioreductive drugs in which a nitrogen mustard is activated by nitroreduction. Comparison is made with the corresponding aziridine derivative CB 195...

journal_title：Cancer chemotherapy and pharmacology

authors： Kestell P,Pruijn FB,Siim BG,Palmer BD,Wilson WR

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:The study investigated the effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. METHODS:Six human colorectal cancer cells were exposed to pemetrexed, gefitinib, and their combination. Antitumor effects were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium br...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang G,Xie X,Liu T,Yang J,Jiao S

更新日期：2013-10-01 00:00:00

abstract：PURPOSE:This study was performed to evaluate the safety and determine the recommended dose (RD) of resminostat monotherapy, an oral histone deacetylase (HDAC) inhibitor, in Japanese patients with advanced solid tumors. METHODS:Resminostat was administered to patients with advanced solid tumors on a 14-day cycle consis...

journal_title：Cancer chemotherapy and pharmacology

authors： Kitazono S,Fujiwara Y,Nakamichi S,Mizugaki H,Nokihara H,Yamamoto N,Yamada Y,Inukai E,Nakamura O,Tamura T

更新日期：2015-06-01 00:00:00

abstract：:There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR ...

journal_title：Cancer chemotherapy and pharmacology

authors： Chiu CH,Chou TY,Chiang CL,Tsai CM

更新日期：2014-10-01 00:00:00

abstract：PURPOSE:An isolated pelvic perfusion technique using multiple agents was used both in patients with unresectable recurrent pelvic neoplasms and as a preoperative therapy for advanced pelvic malignancy. METHODS:The technique consisted of vascular occlusion via transfemoral balloon catheters, circulation and drug infusi...

journal_title：Cancer chemotherapy and pharmacology

authors： Wanebo HJ,Belliveau JF

更新日期：1999-01-01 00:00:00

abstract：:Previous studies have demonstrated that treatment with fludarabine 4 h prior to arabinosylcytosine (ara-C) potentiates the accumulation of the active triphosphate of ara-C (ara-CTP) in leukemic lymphocytes. The clinical efficacy of this combination was evaluated in 15 patients with chronic lymphocytic leukemia (CLL) t...

journal_title：Cancer chemotherapy and pharmacology

authors： Gandhi V,Robertson LE,Keating MJ,Plunkett W

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Troxacitabine (BCH-4556, l-(-)-OddC, Troxatyl) is a novel beta- l-nucleoside analogue with potent antineoplastic activity both in vitro and in several tumor models in vivo, and is presently in phase II clinical trials. The combination of the cytosine analogues troxacitabine and araC (1-beta- d-arabinofuranosylc...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffard DY,Jolivet J,Leblond L,Hamelin B,Ouellet F,Barbeau S,Richard A,Gourdeau H

更新日期：2003-12-01 00:00:00

abstract：PURPOSE:Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide. However, the effect of CyA on the distribution of etoposide in normal tissues, which could affect their toxicity, has not been studied extensively. The purpose of this study ...

journal_title：Cancer chemotherapy and pharmacology

authors： Cárcel-Trullols J,Torres-Molina F,Araico A,Saadeddin A,Peris JE

更新日期：2004-08-01 00:00:00

abstract：:To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen including cis-platinum. Before treatment all values wer...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen PG,Nissen MH,Groth S,Rørth M

更新日期：1985-01-01 00:00:00

abstract：:Both the capacity of healthy human, cancer patient, and mouse plasma proteins to bind flavone acetic acid (FAA) and the qualitative differences in the plasma protein-binding site were studied. The binding capacity of plasma proteins for FAA was saturated within the therapeutic range in both species. The binding of FAA...

journal_title：Cancer chemotherapy and pharmacology

authors： Brodfuehrer J,Valeriote F,Chan K,Heilbrun L,Corbett T

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:A standard chemotherapy regimen for neuroendocrine carcinoma of the gastrointestinal tract (GI-NEC) has not been established. Treatment usually consists of platinum doublets, consistent with the standard treatment for small-cell lung cancer (SCLC), with which it shares clinicopathological similarities. Here, we...

journal_title：Cancer chemotherapy and pharmacology

authors： Asayama M,Fuse N,Yoshino T,Yano T,Tahara M,Doi T,Fujii S,Ohtsu A

更新日期：2011-11-01 00:00:00

abstract：PURPOSE:To determine the safety, the maximal tolerated dose, and to assess for any clinical activity of pomalidomide given to patients with advanced solid tumors. PATIENTS AND METHODS:Patients with incurable solid tumors were enrolled. Two different dosing schedules were explored. In Cohort A patients were given pomal...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Nock C,Bokar J,Krishnamurthi S,Gibbons J,Rodal MB,Ness A,Remick SC,Dreicer R,Dowlati A

更新日期：2012-11-01 00:00:00

abstract：UNLABELLED:Oxaliplatin (OPT), a third-generation platinating agent, is currently being evaluated in a phase II clinical trial in head and neck cancer patients and in a phase I clinical trial in combination with paclitaxel (TXL). PURPOSE:The aim of this study was to investigate the pharmacokinetics and biological corre...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu J,Kraut E,Bender J,Brooks R,Balcerzak S,Grever M,Stanley H,D'Ambrosio S,Gibson-D'Ambrosio R,Chan KK

更新日期：2002-05-01 00:00:00

abstract：:Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC)...

journal_title：Cancer chemotherapy and pharmacology

authors： Chatelut E,Chevreau C,Brunner V,Martinez M,Houin G,Bugat R,Canal P

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes ha...

journal_title：Cancer chemotherapy and pharmacology

authors： Narita Y,Asai A,Kuchino Y,Kirino T

更新日期：2000-01-01 00:00:00

abstract：:The aim of the present investigation was to evaluate the potential cardioprotective effect of reduced glutathione (GSH) against the delayed cardiomyopathy induced by doxorubicin (DXR) in a well-documented rat model. DXR was administered i.v. at a weekly dose of 3 mg/kg for a total of 4 doses; 250 or 500 mg/kg of GSH w...

journal_title：Cancer chemotherapy and pharmacology

authors： Villani F,Galimberti M,Zunino F,Monti E,Rozza A,Lanza E,Favalli L,Poggi P

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory metastatic colorectal can...

journal_title：Cancer chemotherapy and pharmacology

authors： Clarke JM,Blobe GC,Strickler JH,Uronis HE,Zafar SY,Morse M,Dropkin E,Howard L,O'Neill M,Rushing CN,Niedzwiecki D,Watson H,Bolch E,Arrowood C,Liu Y,Nixon AB,Hurwitz HI

更新日期：2019-10-01 00:00:00

abstract：:Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4'demethylepipodophyllotoxin-beta-D-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may h...

journal_title：Cancer chemotherapy and pharmacology

authors： Chapman R,Itri L,Gralla R,Kelsen D,Casper E,Golbey R

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:The blood-brain barrier discriminates the access of several molecules to the brain. This hampers the use of some drugs, as doxorubicin, potentially active for treatment of brain tumors. We explored the feasibility of active modification of the blood-brain barrier protection, by using morphine pretreatment, to a...

journal_title：Cancer chemotherapy and pharmacology

authors： Sardi I,la Marca G,Giovannini MG,Malvagia S,Guerrini R,Genitori L,Massimino M,Aricò M

更新日期：2011-06-01 00:00:00

abstract：PURPOSE:To evaluate the antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a vascular disrupting agent currently under phase II clinical trials in combination with cancer chemotherapy, in rats bearing chemically induced primary mammary tumours. METHODS:Tumours were induced in female Wistar rats by in...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu JJ,Ching LM,Goldthorpe M,Sutherland R,Baguley BC,Kirker JA,McKeage MJ

更新日期：2007-04-01 00:00:00

abstract：PURPOSE:We have previously reported that intra-arterial chemotherapy prolongs the survival of patients with advanced HCC (aHCC); however, whether the response to intra-arterial chemotherapy depends on the etiology of underlying liver cirrhosis (LC) is still unknown. AIM:The aim of this study was to assess any influenc...

journal_title：Cancer chemotherapy and pharmacology

authors： Kanayama M,Nagai H,Sumino Y

更新日期：2009-06-01 00:00:00

abstract：BACKGROUND:Epidemiologic and preclinical data suggest isoflavones have anticancer activity in colorectal malignancy prevention and treatment. This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer. METHODS:Patients who had histol...

journal_title：Cancer chemotherapy and pharmacology

authors： Pintova S,Dharmupari S,Moshier E,Zubizarreta N,Ang C,Holcombe RF

更新日期：2019-09-01 00:00:00

abstract：OBJECTIVE:SDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac, and has anti-tumour activity in chronic lymphocytic leukaemia (CLL). SDX-308 and SDX-309 are more potent, structurally related indole-pyran analogues of SDX-101. The current study was performed to i...

journal_title：Cancer chemotherapy and pharmacology

authors： Lindhagen E,Nissle S,Leoni L,Elliott G,Chao Q,Larsson R,Aleskog A

更新日期：2007-09-01 00:00:00

abstract：BACKGROUND:This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 monoclonal antibody in combination with erlotinib, an epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI) in prior chemotherapy t...

journal_title：Cancer chemotherapy and pharmacology

authors： Shimizu T,Yonesaka K,Hayashi H,Iwasa T,Haratani K,Yamada H,Ohwada S,Kamiyama E,Nakagawa K

更新日期：2017-03-01 00:00:00